VKORC1 (-1639) Polymorphisms do not Affect Long-Term Stability of Anticoagulation with Warfarin
Abohelaika S1, Kamali F1, Wynne H2*
1 Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
2 Department of Older People's Medicine, Freeman Hospital Newcastle upon Tyne NE7 7DN UK.
Department of Older People's Medicine,
Freeman Hospital Newcastle
upon Tyne NE7 7DN UK.
Tel: +44 191 2236161
Fax: +44 191 2231249
Received: October 20, 2015; Accepted: November 17, 2015; Published: November 19, 2015
Citation: Abohelaika S, Kamali F, Wynne H (2015) VKORC1 (-1639) Polymorphisms do not Affect Long-Term Stability of Anticoagulation with Warfarin. Int J Clin Pharmacol Toxicol, 4(6) 192-194. doi: dx.doi.org/10.19070/2167-910X-1500032
Copyright: Wynne H© 2015. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The extent of INR fall following vitamin K supplementation to patients on warfarin is related to VKORC1-1639G>A genotype, with those carrying the GG genotype demonstrating a significantly larger fall in INR compared to those carrying the GA, and AA genotype. We hypothesized that, due to the expected variability in dietary vitamin K intake over time, patients with the VKORC1(-1639)GG polymorphism could have poorer anticoagulation control than GA or AA carriers. 234 atrial fibrillation (AF) patients on warfarin therapy were studied. Anticoagulation control was assessed by the determination of percentage time in therapeutic range (% TTR) of INR, the frequency of INR monitoring and warfarin dose changes over a 12 months period. There were no significant differences between GG GA and AA variants in mean % TTR (66, 61, 68),mean number of INR monitoring events (12.4, 13.5, 13.0) and mean warfarin dose changes (3.9, 4.0, 3.3), respectively. The study results failed to confirm our hypothesis that patients with the VKORC1(-1639) GG variant have poorer anticoagulation control, indicating that the effect of any such influence at the pharmacological level is too small to influence clinically relevant outcomes in our population.
3.Materials and Methods
Warfarin; Anticoagulation; Stroke; Vitamin K; Diet; VKORC1 Polymorphism.
Achieving a stable anticoagulant effect with vitamin K antagonists such as warfarin is important as they have a narrow therapeutic range, with risk of bleeding or thrombosis increasing with over and under-anticoagulation respectively. Outcomes for patients in atrial fibrillation anticoagulated for thromboembolic prophylaxisimprove with more time spent within the desired therapeutic range of an International Normalised ratio (INR) between 2.0-3.0, commonly expressed as the percentage time in therapeutic range (% TTR). Overall survival is improved for warfarin treated groups where TTR is greater than 40%  and a TTR of >58% is needed to be confident that patients will benefit from anticoagulation . Patients with a TTR of ≥ 70% have a 79% reduced risk of stroke compared to those spending <30% of time in range, and have lower mortality rates . Whilst unstable anticoagulation control has been associated with poor drug compliance, poor patient knowledge about anticoagulant treatment, acute or irregular alcohol use and genetics (CYP2C9 and VKORC1 polymorphisms), other factors including variability in and response to vitamin K intake, may contribute to poor stability .
In man, vitamin K is obtained primarily from the diet in the form of phylloquinones which are found in greatest concentration in green leafy vegetables , intake of which varies from day to day. The amount of dietary intake of vitamin K influences warfarin sensitivity and variability in INR . Patients with poor dietary vitamin K intake are more susceptible to fluctuations in anticoagulation control , being more sensitive to day to day changes in vitamin K intake because of limited liver stores to stabilise the production of the functional clotting factors II, VII, IX and X, for which vitamin K is an essential co-factor . Warfarin reduces the regeneration of vitamin K hydroquinone from vitamin K 2, 3-epoxide by inhibiting vitamin K epoxide reductase (VKOR) in the vitamin K cycle . The VKOR enzyme is expressed by the vitamin K epoxide reductase gene, VKORC1, in which a number of common polymorphisms have been identified. These polymorphisms, which include a G > A polymorphismat VKORC1 position -1639 of Intron 1, are associated with altered hepatic VKOR expression and lower warfarin dose requirements [10, 11].
Stability of anticoagulation control can be improved by daily vitamin K supplementation [6, 12], although an initial increase in warfarin dose may be required because of the antagonist effect of vitamin K on the pharmacological activity of warfarin. This varies between different patients and is related to VKORC1-1639G > A genotype, with those carrying the GG genotype demonstrating a significantly larger fall in INR, and requiring a significantly greater increase in warfarin dose, by an average of 33%, compared with 11% for those carrying the GA, and < 1% for those with the AA genotype, following vitamin K supplementation . This is because patients with GG genotype are more efficient at converting vitamin K epoxide to vitamin K, leading to a greater regeneration of vitamin K hydroquinone and subsequently a larger increase in the activation of vitamin K dependent clotting factors compared to patients with the GA and AA genotype .
Based upon the above observation we hypothesized that patients on warfarin therapy with the VKORC1 (-1639) GG polymorphism could have less stable control of anticoagulation than those with GA or AA genotypes as a result of variable dietary intake of vitamin K. We set out to examine this possibility in a cohort of patients on chronic warfarin therapy.
Materials and Methods
The INR values and dose changes of atrial fibrillation patients taking warfarin who had attended the Newcastle upon Tyne Anticoagulation Monitoring Service for at least 18 months for INR testing and dosage advice by staff guided by the DAWN dosing programme , and had VKORC1–1639G > A established in our previous studies of effect of VKORC1 on warfarin dose requirements, were analysed. Since patients commencing warfarin require an initial dose titration period following a loading dose regimen to reach anticoagulation stability, the first six months from the time of warfarin commencement were excluded and the subsequent 12 months data analysed. TTR was calculated by the method of Rosendaal et al . The study was approved by the Regional Ethics Committee and was in accordance with the Helsinki Declaration of 1975.
Statistical analysis was conducted by Statistical Package for Social Sciences version 21 (SPSS). One way analysis of covariance (ANCOVA) was used to examine the difference in TTR, number of INR measurements, mean dose, and number of dose changes among the three VKORC1 variants (GG/GA/AA) taking into account the effect of age and sex covariates.
234 patients [106 (45%) female] were included in the study. The prevalence of VKORC1 AA, GA, and GG variants was 18.4%, 56.4%, and 25.2% respectively. The mean age ± SD between AA, GA, and GG variants groups were similar, 64 ± 18, 63 ± 15, and 63 ± 13, respectively. No statistical differences were observed between the three variants (GG GA AA) in mean TTR (66%, 61%, 68%, respectively), mean number of INR monitoring events (12.4, 13.5, 13.0, respectively), and mean dose changes (3.9, 4.0, 3.3, respectively). Similarly there were no significant differences in these measurements between AA and GG + GA genotypes. However, patients with GG variant required a significantly higher mean warfarin dose compared to those with GA variant (4.0 mg v 3.3 mg; P=0.02) with a mean dose difference of 0.7mg (p=0.02). However, no difference in dose requirement was observed between AA (mean dose=3.2 mg) and GA variants and between AA and GG variants (p=0.07). No influence of age and sex covariates was detected.
Identifying and controlling factors which contribute to intra-individual variability in response to vitamin K antagonists would improve the average time patients stay within their therapeutic INR range, lowering the risk of bleeding or thromboembolic complications associated with over and under-anticoagulation, helping individual patients, especially the very elderly, who have difficulty attending for monitoring and receiving dosing instructions . Polymorphisms in CYP2C9 and VKORC1 are relevant to this in clinical practice as both contribute to the inter-individual variability in coumarin dose requirement and stability of anticoagulation control during the initiation phase of therapy . Excessive anticoagulation occurs more frequently in the carriers of CYP2C9*3 variants (slow S-warfarin metabolisers) at the initiation of treatment and carriers have a lower TTR than those with the wildtype CYP2C9 genotype [17, 18]. Compared to the VKORC1-GG genotype, the GA genotype results in less expression of VKOR enzyme, so that a lower dose of vitamin K antagonist is needed to achieve the same anticoagulant effect . Our results, which show that GG genotype patients required a significantly higher mean warfarin dose compared to GA genotype patients, is consistent with this observation. Results of a study which employed a questionnaire assisted estimation to identify patients with low, medium and high vitamin K intake indicated that the influence of vitamin K intake on warfarin anticoagulation might be VKORC1 genotype dependent as, in subjects with a variant VKORC1 – 1639G allele, the mean daily dose of warfarin was significantly attenuated by low vitamin K intake compared with medium and high whilst no such effects were observed in homozygous patients for the VKORC1-1639A allele [13,19]. We investigated the effect of VKORC1 genotype on long-term control of anticoagulation in patients on chronic warfarin therapy, influenced by dietary vitamin K intake. Given that generally people enjoy having varied diets it is to be expected that there was sufficient variability in the patients’ diet over the 12 months period their anticoagulation control was assessed. One limitation of the study is the lack of information on patients’ comorbidities and concurrent therapy. However, these appear not to have made any significant contribution within the context of this study as the results revealed no difference in % TTR between the three VKORC1 variants. It should be noted that the main objective of the current study was to investigate the long-term stability of anticoagulation control in association with VKORC1 polymorphism with the background of a variable diet. Therefore polymorphisms in genes which either affect warfarin (CYP2C9) or vitamin K metabolism (CYP4F2) would have no effect on anticoagulation control in patients who are on chronic maintenance warfarin therapy.
Our results, which failed to confirm the hypothesis that longterm anticoagulation control is affected more in patients with the VKORC1 (-1639)GG variant, in association with the expected variability in dietary vitamin K, indicate that the effect of any such influence at the pharmacological level is too small to influence clinically relevant outcomes in our population. However, it remains possible that a larger prospective study, in which dietary intakes of vitamin K were measured, might yet establish a statistically significant link between diet, VKORC1 polymorphism and anticoagulation control.
- Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, et al. (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118(20): 2029-2037.
- Baker WL, Cios DA, Sander SD, Coleman CI (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15(3): 244-252.
- Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP (2011) Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 106(5): 968-977.
- Kamali F, Wynne H (2010) Pharmacogenetics of warfarin. Annu Rev Med 61: 63-75.
- Bolton-Smith C, Price RJ, Fenton ST, Harrington DJ, Shearer MJ (2000) Compilation of a provisional UK database for the phylloquinone (vitamin k1) content of foods. Br J Nutr 83(4): 389-399.
- Gebuis EP, Rosendaal FR, van Meegen E, van der Meer FJ (2011) Vitamin k1 supplementation to improve the stability of anticoagulation therapy with vitamin k antagonists: A dose-finding study. Haematologica 96(4): 583- 589.
- Sconce E, Khan T, Mason J, Noble F, Wynne H, et al. (2005) Patients with unstable control have a poorer dietary intake of vitamin k compared to patients with stable control of anticoagulation. Thromb Haemost 93(5): 872-875.
- Shearer MJ (1995) Vitamin k. Lancet 345(8944): 229-234.
- Mosterd JJ, Thijssen HH (1992) The relationship between the vitamin k cycle inhibition and the plasma anticoagulant response at steady-state swarfarin conditions in the rat. J Pharmacol ExpTher 260(3): 1081-1085.
- D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, et al. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2): 645-649.
- Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22): 2285-2293.
- Sconce E, Avery P, Wynne H, Kamali F (2007) Vitamin k supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2419-2423.
- Sconce E, Avery P, Wynne H, Kamali F (2008) Vitamin k epoxide reductase complex subunit 1 (VKORC1 ) polymorphism influences the anticoagulationresponse subsequent to vitamin k intake: A pilot study. J Thromb Haemost 6(7): 1226-1228.
- 4S Information Systems Ltd TS, Milnthorpe, Cumbria, LA7 7QJ www.4s-dawn.com
- Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3): 236-239.
- Tan KM, Tallon E, Noone I, Hughes G, O'Shea D, et al. (2012) Difficulties encountered by the very elderly with atrial fibrillation on warfarin attending an outpatient anticoagulant monitoring service. Eur Geriatr Med 78-81.
- Schalekamp T, Brasse BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, et al. (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects over anticoagulation. Clin Pharmacol Ther 80(1): 13-22.
- Tassies D, Freire C, Pijoan J, Maragall S, Monteagudo J, et al. (2002) Pharmacogenetics of acenocoumarol: Cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Haematologica 87(11): 1185-1191.
- Saito R, Takeda K, Yamamoto K, Nakagawa A, Aoki H, et al. (2014) Nutripharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype- dependent influence of dietary vitamin k intake. J Thromb Thrombolysis: 38(1): 105-114.